Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
boston blog main
boston top stories
clinical trials
life sciences
national blog main
2
×
san francisco blog main
abbvie
allergan
alzheimer's disease
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bluebird bio
crispr
cynthia collins
deals
duchenne muscular dystrophy
dyne therapeutics
editas medicine
facioscapulohumeral muscular dystrophy
gene editing
gene therapy
joshua brumm
kaleido biosciences
leber congenital amaurosis type 10
michelle robertson
muscular dystrophy
myotonic dystrophy type 1
national top stories
new york blog main
parkinson's disease
rare disease drugs
rare diseases
romesh subramanian
san diego blog main
susanna high
vertex pharmaceuticals
What
experimental
2
×
genetic
2
×
medicines
2
×
abbvie
ago
alliance
biotech
biotechs
considering
data
diseases
drug
dyne
early
editas
editing
exits
expected
eyes
gene
having
humans
ipo
ipos
long
muscle
pact
partnership
pruning
rare
reach
research
returning
rights
terminated
therapeutics
treatment
worked
Language
unset
Current search:
experimental
×
medicines
×
" national blog main "
×
genetic
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact